GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forty Seven Inc (NAS:FTSV) » Definitions » Degree of Financial Leverage

Forty Seven (Forty Seven) Degree of Financial Leverage : 0.00 (As of Dec. 2019)


View and export this data going back to 2018. Start your Free Trial

What is Forty Seven Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Forty Seven's Degree of Financial Leverage for the quarter that ended in Dec. 2019 was 0.00. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Forty Seven's Degree of Financial Leverage or its related term are showing as below:

FTSV's Degree of Financial Leverage is not ranked *
in the Biotechnology industry.
Industry Median: 0.96
* Ranked among companies with meaningful Degree of Financial Leverage only.

Forty Seven Degree of Financial Leverage Historical Data

The historical data trend for Forty Seven's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forty Seven Degree of Financial Leverage Chart

Forty Seven Annual Data
Trend Dec16 Dec17 Dec18 Dec19
Degree of Financial Leverage
- - - -

Forty Seven Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Forty Seven's Degree of Financial Leverage

For the Biotechnology subindustry, Forty Seven's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Forty Seven's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forty Seven's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Forty Seven's Degree of Financial Leverage falls into.



Forty Seven Degree of Financial Leverage Calculation

Forty Seven's Degree of Financial Leverage for the quarter that ended in Dec. 2019 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -2.4 (Dec. 2019) / -3.75 (Dec. 2018) - 1 )/( -88.532 (Dec. 2019) / -72.105 (Dec. 2018) - 1 )
=-0.36/0.2278
=-1.58***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Forty Seven  (NAS:FTSV) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Forty Seven Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Forty Seven's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Forty Seven (Forty Seven) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1490 O’Brien Drive, Suite A, Menlo Park, CA, USA, 94025
Forty Seven Inc is a clinical-stage immuno-oncology company. It is engaged in developing novel checkpoint therapies to activate macrophages and help the patients in their fight against cancer. It founded that blocking CD47, a key signaling molecule that is overexpressed on cancer cells renders tumors susceptible to macrophages. It is also preparing investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation conditioning regimens. FSI-189, an anti-SIRP-alpha antibody, is being developed for the treatment of cancer, and certain non-oncology conditions, including transplantation conditioning.
Executives
Dennis Henner director THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Kristine M Ball director C/O RELYPSA, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Ann D Rhoads officer: Chief Financial Officer 4000 NORTH FIRST STREET, SAN JOSE CA 95134
Ian T Clark director SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Jeffrey W Bird director 755 PAGE MILL RD STE A-200, PALO ALTO CA 94304-1005
Lightspeed General Partner X, L.p. 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Lightspeed Ultimate General Partner X, Ltd. 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Jeremy Liew 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Lightspeed Venture Partners X, L.p. 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Barry Eggers 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Peter Nieh 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Ravi Mhatre 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Stephen A Schwarzman 10 percent owner C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Clarus Iii L.l.c. 10 percent owner C/O THE BLACKSTONE GROUP L.P., 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Inc. 10 percent owner 345 PARK AVENUE, NEW YORK NY 10154

Forty Seven (Forty Seven) Headlines

From GuruFocus